Detalle Publicación


Epigenetic markers associated with metformin response and intolerance in drug-naive patients with type 2 diabetes

Autores: García Calzón, Sonia (Autor de correspondencia); Perfilyev, A.; Martinell, M.; Ustinova, M. ; Kalamajski, S.; Franks, P. W. ; Bacos, K. ; Elbere, I. ; Pihlajamaki, J. ; Volkov, P. ; Vaag, A. ; Groop, L. ; Maziarz, R. ; Klovins, J.; Ahlqvist, E. ; Ling, C. (Autor de correspondencia)
ISSN: 1946-6234
Volumen: 12
Número: 561
Páginas: eaaz1803
Fecha de publicación: 2020
Metformin is the first-line pharmacotherapy for managing type 2 diabetes (T2D). However, many patients with T2D do not respond to or tolerate metformin well. Currently, there are no phenotypes that successfully predict glycemic response to, or tolerance of, metformin. We explored whether blood-based epigenetic markers could discriminate metformin response and tolerance by analyzing genome-wide DNA methylation in drug-naive patients with T2D at the time of their diagnosis. DNA methylation of 11 and 4 sites differed between glycemic responders/nonresponders and metformin-tolerant/intolerant patients, respectively, in discovery and replication cohorts. Greater methylation at these sites associated with a higher risk of not responding to or not tolerating metformin with odds ratios between 1.43 and 3.09 per 1-SD methylation increase. Methylation risk scores (MRSs) of the 11 identified sites differed between glycemic responders and nonresponders with areas under the curve (AUCs) of 0.80 to 0.98. MRSs of the 4 sites associated with future metformin intolerance generated AUCs of 0.85 to 0.93. Some of these blood-based methylation markers mirrored the epigenetic pattern in adipose tissue, a key tissue in diabetes pathogenesis, and genes to which these markers were annotated to had biological functions in hepatocytes that altered metformin-related phenotypes. Overall, we could discriminate between glycemic responders/nonresponders and participants tolerant/intolerant to metformin at diagnosis by measuring blood-based epigenetic markers in drug-naive patients with T2D. This epigenetics-based tool may be further developed to help patients with T2D receive optimal therapy.